PHAT
Phathom Pharmaceuticals, Inc. NASDAQ Listed Oct 25, 2019$12.23
Mkt Cap $975.4M
52w Low $2.21
62.2% of range
52w High $18.31
50d MA $11.61
200d MA $12.63
P/E (TTM)
-4.0x
EV/EBITDA
-7.1x
P/B
—
Debt/Equity
-0.0x
ROE
50.5%
P/FCF
-7.3x
RSI (14)
—
ATR (14)
—
Beta
0.61
50d MA
$11.61
200d MA
$12.63
Avg Volume
1.1M
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
100 Campus Drive · Florham Park, NJ 07932 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | -0.17 | -0.37 | -117.6% | 11.78 | -2.7% | -4.9% | +7.2% | +7.2% | -2.1% | +0.6% | — |
| Feb 26, 2026 | BMO | -0.32 | -0.16 | +49.9% | 12.32 | +5.5% | +10.1% | -7.4% | -8.8% | -3.6% | +0.1% | — |
| Oct 30, 2025 | BMO | -0.30 | -0.15 | +50.0% | 13.53 | +3.5% | -1.6% | +1.8% | +1.3% | -1.7% | -1.6% | — |
| Aug 7, 2025 | BMO | -0.76 | -0.79 | -3.9% | 8.68 | +6.1% | +8.3% | +3.6% | +5.5% | +1.0% | +1.0% | — |
| May 1, 2025 | BMO | -1.06 | -1.07 | -0.9% | 4.29 | -6.8% | -21.7% | -17.9% | -6.5% | -7.0% | +0.0% | — |
| Mar 6, 2025 | BMO | -1.29 | -0.79 | +38.8% | 6.08 | -5.3% | -3.0% | -14.2% | -13.0% | +8.9% | +4.4% | — |
| Nov 7, 2024 | BMO | -1.57 | -1.32 | +15.9% | 18.00 | +4.3% | +2.8% | -8.9% | -22.3% | -27.3% | +2.4% | — |
| Aug 8, 2024 | BMO | -1.20 | -1.25 | -4.2% | 10.81 | +6.4% | +8.7% | +0.0% | +2.4% | +1.2% | +2.2% | — |
| May 9, 2024 | BMO | -1.43 | -1.42 | +0.7% | 10.10 | -4.0% | -0.1% | -5.6% | +1.5% | +7.4% | +0.2% | — |
| Mar 7, 2024 | BMO | -0.92 | -0.80 | +13.0% | 9.73 | +7.8% | -6.6% | -2.3% | -7.0% | -1.1% | -2.1% | — |
| Nov 9, 2023 | BMO | -0.95 | -0.76 | +20.0% | 7.82 | +7.2% | +0.5% | -4.5% | -4.8% | -0.7% | +3.4% | — |
| Aug 10, 2023 | BMO | -0.95 | -0.84 | +11.6% | 15.13 | +0.5% | +3.7% | -0.7% | -1.2% | +0.2% | -2.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | Barclays | Upgrade | Equal Weight → Overweight | — | $10.79 | $11.26 | +4.4% | -1.9% | -0.5% | +5.5% | +0.3% | +1.8% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $13.56 | $13.53 | -0.2% | -7.4% | -8.8% | -3.6% | +0.1% | -2.9% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.31 | $14.43 | +8.4% | +1.8% | +1.3% | -1.7% | -1.6% | -1.8% |
| Jun 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.92 | $9.18 | +2.9% | -1.0% | +1.6% | +0.8% | +11.0% | +6.1% |
| Jun 9 | Craig-Hallum | Maintains | Buy → Buy | — | $8.92 | $9.18 | +2.9% | -1.0% | +1.6% | +0.8% | +11.0% | +6.1% |
| Jun 6 | Needham | Maintains | Buy → Buy | — | $4.69 | $4.80 | +2.3% | +90.2% | -1.0% | +1.6% | +0.8% | +11.0% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.36 | $3.38 | +0.6% | -17.9% | -6.5% | -7.0% | +0.0% | -4.6% |
| May 2 | Guggenheim | Maintains | Buy → Buy | — | $3.36 | $3.38 | +0.6% | -17.9% | -6.5% | -7.0% | +0.0% | -4.6% |
| May 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $3.36 | $3.38 | +0.6% | -17.9% | -6.5% | -7.0% | +0.0% | -4.6% |
| May 2 | Craig-Hallum | Maintains | Buy → Buy | — | $3.36 | $3.38 | +0.6% | -17.9% | -6.5% | -7.0% | +0.0% | -4.6% |
| Apr 21 | Needham | Maintains | Buy → Buy | — | $4.03 | $4.00 | -0.7% | -3.2% | +1.5% | +1.5% | +2.5% | -0.2% |
| Apr 17 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.22 | $4.30 | +1.9% | -4.5% | -3.2% | +1.5% | +1.5% | +2.5% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $4.25 | $4.16 | -2.1% | +4.2% | -7.2% | +18.7% | -5.1% | +3.0% |
| Apr 2 | Needham | Maintains | Buy → Buy | — | $5.12 | $4.98 | -2.7% | +7.2% | -8.7% | -2.6% | -0.2% | -12.7% |
| Apr 2 | Guggenheim | Maintains | Buy → Buy | — | $5.12 | $4.98 | -2.7% | +7.2% | -8.7% | -2.6% | -0.2% | -12.7% |
| Mar 10 | Goldman Sachs | Maintains | Neutral → Neutral | — | $5.06 | $5.02 | -0.8% | -13.0% | +8.9% | +4.4% | -15.6% | +4.5% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.90 | $5.77 | -2.2% | -14.2% | -13.0% | +8.9% | +4.4% | -15.6% |
| Mar 6 | Needham | Maintains | Buy → Buy | — | $6.08 | $5.76 | -5.3% | -3.0% | -14.2% | -13.0% | +8.9% | +4.4% |
| Jan 10 | Needham | Maintains | Buy → Buy | — | $6.95 | $6.91 | -0.6% | -0.1% | -4.6% | +2.6% | +5.0% | -2.4% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.40 | $8.42 | +0.2% | -4.9% | -1.3% | +3.2% | +2.8% | -4.5% |
| Dec 11 | Needham | Maintains | Buy → Buy | — | $8.93 | $8.98 | +0.6% | -5.9% | -4.9% | -1.3% | +3.2% | +2.8% |
| Sep 13 | Needham | Maintains | Buy → Buy | — | $19.50 | $19.67 | +0.9% | -6.2% | +3.2% | -2.1% | +4.0% | -2.7% |
| Sep 6 | Needham | Maintains | Buy → Buy | — | $17.95 | $17.78 | -0.9% | -1.3% | -0.7% | +1.8% | +4.4% | +4.3% |
| Aug 30 | Needham | Maintains | Buy → Buy | — | $16.30 | $16.30 | +0.0% | +1.3% | -1.7% | +4.7% | +5.6% | -1.3% |
| Aug 23 | Needham | Maintains | Buy → Buy | — | $12.81 | $12.99 | +1.4% | +8.0% | +0.7% | +12.8% | +3.1% | +0.6% |
| Aug 19 | Needham | Maintains | Buy → Buy | — | $12.45 | $13.05 | +4.8% | +3.5% | -1.1% | +1.8% | -1.3% | +8.0% |
| Aug 12 | Needham | Maintains | Buy → Buy | — | $11.75 | $11.89 | +1.2% | +2.4% | +1.2% | +2.2% | +5.4% | -5.0% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.75 | $11.89 | +1.2% | +2.4% | +1.2% | +2.2% | +5.4% | -5.0% |
| Aug 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $11.75 | $11.88 | +1.1% | +0.0% | +2.4% | +1.2% | +2.2% | +5.4% |
| Jul 26 | Needham | Maintains | Buy → Buy | — | $11.28 | $11.49 | +1.9% | +4.1% | -2.4% | +0.8% | +2.3% | -3.3% |
| Jul 22 | Needham | Maintains | Buy → Buy | — | $10.95 | $10.99 | +0.4% | +8.5% | +2.1% | -5.5% | -1.6% | +4.1% |
| Jul 19 | Needham | Maintains | Buy → Buy | — | $11.18 | $11.29 | +1.0% | -2.1% | +8.5% | +2.1% | -5.5% | -1.6% |
| Jul 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.18 | $11.29 | +1.0% | -2.1% | +8.5% | +2.1% | -5.5% | -1.6% |
| Jul 12 | Needham | Maintains | Buy → Buy | — | $11.32 | $11.50 | +1.6% | +2.9% | +8.8% | -3.6% | -0.9% | -7.7% |
| Jul 8 | Needham | Maintains | Buy → Buy | — | $10.30 | $10.34 | +0.4% | +1.3% | +0.8% | -0.6% | +8.3% | +2.9% |
| Jun 28 | Needham | Maintains | Buy → Buy | — | $10.40 | $10.52 | +1.2% | -1.0% | +5.0% | -5.2% | +0.0% | +0.5% |
| Jun 21 | Needham | Maintains | Buy → Buy | — | $11.81 | $11.77 | -0.3% | -6.2% | -2.3% | -4.6% | -1.1% | +1.8% |
| Jun 14 | Needham | Maintains | Buy → Buy | — | $10.95 | $10.73 | -2.0% | +3.7% | +3.1% | +1.5% | -0.5% | -6.2% |
| Jun 7 | Needham | Maintains | Buy → Buy | — | $9.68 | $9.60 | -0.8% | +9.5% | +1.3% | +2.7% | -1.5% | +0.7% |
| May 31 | Needham | Maintains | Buy → Buy | — | $10.19 | $10.23 | +0.4% | -7.6% | +9.7% | +0.3% | -0.5% | -6.1% |
| May 24 | Needham | Maintains | Buy → Buy | — | $10.30 | $10.40 | +1.0% | +1.9% | -2.0% | -2.0% | +1.1% | -7.6% |
| May 17 | Needham | Maintains | Buy → Buy | — | $10.69 | $10.72 | +0.3% | -1.4% | +3.3% | -1.5% | -3.5% | -0.5% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.09 | $10.16 | +0.7% | -5.5% | +1.5% | +7.4% | +0.2% | +2.7% |
| May 10 | Needham | Maintains | Buy → Buy | — | $10.09 | $10.16 | +0.7% | -5.5% | +1.5% | +7.4% | +0.2% | +2.7% |
| May 9 | Needham | Maintains | Buy → Buy | — | $10.10 | $9.70 | -4.0% | -0.1% | -5.6% | +1.5% | +7.4% | +0.2% |
| May 8 | Needham | Maintains | Buy → Buy | — | $10.24 | $10.13 | -1.1% | -1.4% | -0.1% | -5.6% | +1.5% | +7.4% |
| May 3 | Needham | Maintains | Buy → Buy | — | $9.76 | $10.35 | +6.0% | +2.9% | +8.0% | -5.5% | -1.4% | -0.1% |
| Apr 26 | Needham | Maintains | Buy → Buy | — | $9.10 | $9.08 | -0.2% | +0.9% | +1.9% | -3.4% | +2.5% | +5.4% |
| Apr 19 | Needham | Maintains | Buy → Buy | — | $9.48 | $9.48 | +0.0% | -5.4% | +0.4% | +0.6% | +0.7% | -0.2% |
| Apr 12 | Needham | Maintains | Buy → Buy | — | $10.47 | $10.54 | +0.7% | -3.2% | -1.2% | +0.1% | -2.3% | -3.3% |
No insider trades available.
8-K
Phathom Pharmaceuticals, Inc. -- 8-K Filing
Phathom Pharmaceuticals reported Q1 2026 results and provided business updates on gastrointestinal disease treatments, with specific financial metrics and operational progress detailed in the filing.
Apr 30
8-K
Phathom Pharmaceuticals, Inc. -- 8-K Filing
Phathom Pharmaceuticals reported Q4 and full-year 2025 results with 2026 guidance, providing investors visibility into the GI-focused biopharmaceutical company's commercial progress and financial trajectory.
Feb 26
Data updated apr 26, 2026 7:32pm
· Source: massive.com